Clinical trials: Crohn's Disease, Active, open to volunteers
IBS, Ulcerative Colitis, Active
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
- Conditions
- IBS, Ulcerative Colitis, Active, Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms), Healthy Controls
- Trial name
- NCT02421705
- Testing
- Sample collection
- Where
- Belgium
- Volunteers
- 99,999,999 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Moderately to Severely Active Crohns Disease
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with…
- Trial name
- SIBERITE-1 (NCT06819878)
- Testing
- Afimkibart
- Where
- 375 sites in United States, Argentina and 36 more
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
Moderately to Severely Active Crohns Disease
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
- Trial name
- SIBERITE-PEDS (NCT07298421)
- Testing
- Afimkibart
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Moderately to Severely Active Crohns Disease
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's…
- Trial name
- SIBERITE-2 (NCT06819891)
- Testing
- Afimkibart
- Where
- 203 sites in United States, Argentina and 25 more
- Volunteers
- 425 people
- Sponsor
- Hoffmann-La Roche
Crohn's Disease, Active, Crohn's Disease (CD)
Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease
The purpose of this study is to test the effect of an anti-inflammatory diet tailored for patients living in the United States with Crohn's Disease (CD) on clinical symptoms and disease inflammation and to identify biomarkers of…
- Conditions
- Crohn's Disease, Active, Crohn's Disease (CD), Diet Interventions
- Trial name
- NCT07671872
- Testing
- Catered Anti-Inflammatory Diet, Diet Guidance for Usual Diet
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- University of Miami
Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
This study is a real - world clinical research of adalimumab. The project plans to enroll 30 subjects, aiming to evaluate the incidence of serious adverse events (SAEs) within 12, 26, and 52 weeks after treatment; as well as the…
- Trial name
- NCT07564505
- Testing
- Adalimumab Solution for Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Crohn's Disease, Active
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
This is a multicenter non-randomized prospective open label trial of partial enteral nutrition (PEN) among patients with active Crohn's disease (CD) starting standard of care advanced therapy.
- Trial name
- PANDORA (NCT07356232)
- Testing
- Partial enteral nutrition - orally consumed formula
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
Moderately to Severely Active Crohn Disease
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and…
- Trial name
- ENHANCE-CD (NCT06456593)
- Testing
- Obefazimod
- Where
- 149 sites in United States, Belgium and 10 more
- Volunteers
- 212 people
- Sponsor
- Abivax S.A.
Moderately to Severely Active Crohn's Disease, Crohn Disease
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes.
- Conditions
- Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
- Trial name
- VECTORS (NCT06257706)
- Testing
- Vedolizumab
- Where
- 69 sites in United States, Australia and 11 more
- Volunteers
- 304 people
- Sponsor
- Alimentiv Inc.
Crohn's Diseases, Active Anal Fistula
Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease
Anal fistula is the most common perianal lesion of Crohn's disease (CD), and the incidence of anal fistula in eastern CD population is significantly higher than that in Western population.
- Conditions
- Crohn's Diseases, Active Anal Fistula, Upadacitinib
- Trial name
- NCT06902987
- Testing
- Upadacitinib
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University